Assessment of abuse of tianeptine from a reimbursement database using 'doctor-shopping' as an indicator

Fundamental and Clinical Pharmacology

Volumn 26, Issue 2, 2012, Pages 286-294

  Rouby, Frank ^a,b   Pradel, Vincent ^a,b,c   Frauger, Elisabeth ^a,b   Pauly, Vanessa ^c   Natali, François ^d   Reggio, Patrick ^d   Thirion, Xavier ^c   Micallef, Joëlle ^a,b  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Doctor shopping; Pharmacoepidemiology; Prescription drug abuse; Tianeptine

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BROMAZEPAM; CITALOPRAM; CLONAZEPAM; DIAZEPAM; FLUNITRAZEPAM; FLUOXETINE; LORAZEPAM; LORMETAZEPAM; MIANSERIN; MIRTAZAPINE; OXAZEPAM; PAROXETINE; SERTRALINE; TIANEPTINE; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; ARTICLE; DATA BASE; DOCTOR SHOPPING; DRUG ABUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REIMBURSEMENT;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; DATABASES, FACTUAL; FRANCE; HUMANS; MALE; PHARMACOEPIDEMIOLOGY; PHYSICIAN'S PRACTICE PATTERNS; SUBSTANCE-RELATED DISORDERS; THIAZEPINES;

EID: 84858025163     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00906.x     Document Type: Article

References (48)

1. Griffiths R.R., Bigelow G.E., Ator N.A. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. (2003) 70 S41-S54.
2. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. (2003) 70 S13-S40.
3. Brady K.T., Lydiard R.B., Brady J.V. Assessing abuse liability in clinical trials. Drug Alcohol Depend. (2003) 70 S87-S95.
4. Schoedel K.A., Sellers E.M. Assessing abuse liability during drug development: changing standards and expectations development. Clin. Pharmacol. Ther. (2008) 83 622-626.
5. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. (2009) 105 S14-S25.
6. Henningfield J.E., Schuster C.R. Risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend. (2009) 105 S56-S64.
7. Dart R.C. Signal detection in post-marketing surveillance for controlled substances Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend. (2009) 105 S26-S32.
8. Dasgupta N., Schnoll S.H. Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend. (2009) 105 S33-S41.
9. Kessler D. A Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA (1993) 269 2765-2768.
10. MEDWATCH, 2002. Available from: Accessed 14 October 2010.
11. Thirion X., Barrau K., Micallef J., Haramburu F., Lowenstein W., San-Marco J.L. Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction. Ann. Med. Interne (Paris) (2000) 15124 87.
12. Thirion X., Micallef J., Barrau K., Djezzar S., San-Marco J.L., Lagier G. Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme. Eur. Addict. Res. (2001) 7 32-36.
13. Barrau K., Thirion X., Micallef J., Chuniaud-Louche C., Bellemin B., San-Marco J.L. Comparison of methadone and high dosage buprenorphine users in French care centres. Addiction (2001) 96 1433-1441.
14. Micallef J., Pradel V., Thirion X., Frauger E., the CEIP Network. Indicators abuse and liabilities of benzodiazepines using OPPIDUM program. Fundam. Clin. Pharmacol. (2006) 20 150.
15. Modelon H., Frauger E., Laurenceau D., Thirion X., Mallaret M., Micallef J. Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network. Therapie (2007) 62 337-346.
16. Bergman U., Dahl-Puustinen M.L. Use of prescription forgeries in a drug abuse surveillance network. Eur. J. Clin. Pharmacol. (1989) 36 621-623.
17. Lapeyre-Mestre M., Damase-Michel C., Adams P., Michaud P., Montastruc J.L. Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrenees. Eur. J. Clin. Pharmacol. (1997) 52 37-39.
18. Boeuf O Lapeyre-Mestre M. Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf. (2007) 30 265-276.
19. Pradel V., Thirion X., Ronfle E., Masut A., Micallef J., Begaud B. Assessment of doctor-shopping for high dosage buprenorphine maintenance treatment in a French region: development of a new method for prescription database. Pharmacoepidemiol. Drug Saf. (2004) 13 473-481.
20. Pradel V., Frauger E., Thirion X. et al. Impact of a prescription monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol. Drug Saf. (2009) 18 36-43.
21. Pradel V., Delga C., Rouby F., Micallef J., Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator. CNS Drugs (2010) 24 611-620.
22. Haddad P. Do antidepressants have any potential to cause addiction? J. Psychopharmacol. (1999) 13 300-307.
23. Castot A., Benzaken C., Wagniart F., Efthymiou M.L. Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance. Therapie (1990) 45 399-405.
24. WHO Expert Committee on Drug Dependence. World Health Organ. Tech. Rep. Ser. WHO Expert Committee on Drug Dependence thirty-third report (2003) 915, i-v, 1-26, back cover.
25. Mounier G., Marsille F., Guy C., Beyens M.N., Kuhn R., Mismetti P. Acne associated with tianeptine treatment: 13 cases report from french pharmacovigilance database. Fundam. Clin. Pharmacol. (2010) 24 87.
26. Favre J.D., Guelfi-Sozzi C., Delalleau B., Loo H. Tianeptine and alcohol dependence. Eur. Neuropsychopharmacol. (1997) 7 S347-S351.
27. Vandel P., Regina W., Bonin B., Sechter D., Bizouard P. Abuse of tianeptine. A case report. Encephale (1999) 25 672-673.
28. Guillem E., Lepine J.P. Does addiction to antidepressants exist? About a case of one addiction to tianeptine. Encephale (2003) 29 456-459.
29. Leterme L., Singlan Y.S., Auclair V., Le Boisselier R., Frimas V. Misuse of tianeptine: five cases of abuse. Ann. Med. Interne (Paris) (2003) 154 S58-S63.
30. Saatcioglu O., Erim R., Cakmak D. A case of tianeptine abuse. Turk Psikiyatri Derg. (2006) 17 72-75.
31. Kisa C., Bulbul D.O., Aydemir C., Goka E. Is it possible to be dependent to Tianeptine, an antidepressant? A case report. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) 31 776-778.
32. Thirion X., Lapierre V., Micallef J. et al. Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend. (2002) 65 197-204.
33. Victori-Vigneau C., Basset G., Jolliet P. How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France. Eur. J. Clin. Pharmacol. (2006) 62 311-316.
34. Pradel V., Micallef J., Blin O. Prescription switch studies: objectives, methods and limits. Therapie (2007) 62 31-38.
35. Frauger E., Pauly V., Thirion X. et al. Estimation of clonazepam abuse liability: a new method using a reimbursed drug database. Int. Clin. Psychopharmacol. (2009) 24 318-324.
36. Lecadet J., Vidal P., Baris B. et al. Psychotropic medications: prescriptions and use in metropolitan france. I. National Data For 2000. Revue Médicale de l'Assurance Maladie. (2003) 34 75-84.
37. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry (2005) 66(Suppl 9) 31-41.
38. Micallef-Roll J., Lapeyre-Mestre M., on behalf of the Association Française des centres d'Evaluation et d'Information sur Pharmacodependance-Addictovigilance. How to evaluate, and prevent the abuse and dependence on hypnotic/anxiolytic drugs. Therapie (2009) 64 355-364.
39. Mintzer M.Z., Griffiths R.R. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav. Pharmacol. (2005) 16 579-584.
40. Simmons M.M., Cupp M.J. Use and abuse of flunitrazepam. Ann. Pharmacother. (1998) 32 117-119.
41. Druid H., Holmgren P., Ahlner J. Flunitrazepam: an evaluation of use, abuse and toxicity. Forensic Sci. Int. (2001) 122 136-141.
42. Woods J.H., Winger G. Abuse liability of flunitrazepam. J. Clin. Psychopharmacol. (1997) 17 1S-57S.
43. Wilde M.I., Benfield P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs (1995) 49 411-439.
44. Wagstaff A.J., Ormrod D., Spencer C.M. Tianeptine: a review of its use in depressive disorders. CNS Drugs (2001) 15 231-259.
45. Niederhofer H., Staffen W., Mair A. Tianeptine may be a useful adjunct in the treatment of alcohol dependence of adolescents. Alcohol. Clin. Exp. Res. (2003) 27 136.
46. Mennini T., Mocaer E., Garattini S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. (1987) 336 478-482.
47. Saccheti G., Bonini I., Waeterloos G.C., Samanin R. Tianeptine raises dopamine and blocks stress-induced noradrenaline release in the rat frontal cortex. Eur. J. Pharmacol. (1993) 236 71-75.
48. Invernizzi R., Pozzi L., Garattini S., Samanin R. Tianeptine increases the extracellular concentrations of dopamine in the nucleus accumbens by a serotonin-independent mechanism. Neuropharmacology (1992) 31 221-227.